Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | Director | June 30, 2021 | July 01, 2021 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director · President & CEO | March 16, 2022 | March 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kaleido Biosciences, Inc.
Report date June 30, 2021 · Filed July 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.44 · Expires 2031-06-29 | Direct | 15,000 |
Reported balance
After 2021-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 15,000 · Balance 15,000 |
Spyre Therapeutics, Inc.
Report date March 16, 2022 · Filed March 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 550,540 |
Reported balance
After 2022-03-16 transaction · row 1
1 source rowRow 1 · 2022-03-16 · Purchase · Acquired 80,079 · Balance 550,540 F1: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.92 to $2.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein. |
| Common StockSEC Table I · non-derivative | IndirectBy trusts | 266,295 |
Reported balance
Holding disclosure · report date 2022-03-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 266,295 F2: Includes 57,450 shares of common stock held by the Anthony G. Quinn Irrevocable Trust of 2018 and 208,845 shares of common stock held by the Quinn Family Irrevocable Trust of 2021(together, the "Trusts"). The Reporting Person's spouse is trustee of the Trusts. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.92 to $2.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F2: Includes 57,450 shares of common stock held by the Anthony G. Quinn Irrevocable Trust of 2018 and 208,845 shares of common stock held by the Quinn Family Irrevocable Trust of 2021(together, the "Trusts"). The Reporting Person's spouse is trustee of the Trusts.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Generation Bio Co.
Report date February 09, 2026 · Filed February 09, 2026
Section 16 reporting ended · disclosed 2026-02-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 1
1 source rowRow 1 · 2026-02-09 · Other · Disposed 29,928 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | IndirectBy Quinn Family Irrevocable Trust of 2021 | 0 |
Reported balance
After 2026-02-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-09 · Other · Disposed 7,283 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F3: The securities are directly held by the Quinn Family Irrevocable Trust of 2021 (the "Quinn Family Trust"), formerly the Spousal Lifetime Access Trust. Anthony G. Quinn is the settlor of the Quinn Family Trust, M. Clare Quinn is the trustee for the Quinn Family Trust and the Quinn Family Trust is for the benefit of M. Clare Quinn, Emma, Richard, and Charles Quinn. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.87 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-09 · Disposition to issuer · Disposed 3,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $190.00 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-09 · Disposition to issuer · Disposed 5,200 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $265.90 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-09 · Disposition to issuer · Disposed 1,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.90 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-09 · Disposition to issuer · Disposed 1,920 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.30 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-09 · Disposition to issuer · Disposed 2,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.20 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-09 · Disposition to issuer · Disposed 6,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),
F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F3: The securities are directly held by the Quinn Family Irrevocable Trust of 2021 (the "Quinn Family Trust"), formerly the Spousal Lifetime Access Trust. Anthony G. Quinn is the settlor of the Quinn Family Trust, M. Clare Quinn is the trustee for the Quinn Family Trust and the Quinn Family Trust is for the benefit of M. Clare Quinn, Emma, Richard, and Charles Quinn.
F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2019 Filed May 17, 2019 17:04 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 5,520 | $6.83 | $37,690.56 |
DisclosureSEC source: 0001567619-19-011561 · doc1.xml · nonDerivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,928 F3 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.75 to $6.93 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| May 15, 2019 Filed May 17, 2019 17:04 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 6,256 | $6.76 | $42,269.29 |
DisclosureSEC source: 0001567619-19-011561 · doc1.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,408 F2 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.65 to $6.87 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| March 04, 2019 Filed Mar 4, 2019 20:13 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionSeries B Preferred Stock · Derivative | 25,707 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-005963 · doc4.xml · derivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,853 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. Read SEC document |
| March 04, 2019 Filed Mar 4, 2019 20:13 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionCommon Stock | 12,853 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-005963 · doc4.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 17:08 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantStock Option (right to buy) · Derivative | 280,000 | $0.00 Strike: $8.36 | $0.00 |
DisclosureSEC source: 0001567619-19-005835 · doc1.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 28, 2019, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 15, 2019 Filed May 17, 2019 17:04 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 719 | $7.10 | $5,103.46 |
DisclosureSEC source: 0001567619-19-011561 · doc1.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,152 F1 · shares: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:15 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionStock Option (right to buy) · Derivative | 7,433 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001567619-19-002796 · doc1.xml · derivative · entry 4 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,517 Underlying: Common Stock · 7,433 shares Expires 2028-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:15 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionStock Option (right to buy) · Derivative | 1,323 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001567619-19-002796 · doc1.xml · derivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662 Underlying: Common Stock · 1,323 shares Expires 2026-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:15 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 7,433 | $6.31 | $46,902.23 |
DisclosureSEC source: 0001567619-19-002796 · doc1.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:15 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 1,323 | $5.46 | $7,223.58 |
DisclosureSEC source: 0001567619-19-002796 · doc1.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2018 Filed Feb 14, 2022 17:19 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GiftCommon Stock | 57,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 57,450 F1 · ownership.nature: These securities are held by the Anthony G. Quinn Irrevocable Trust of 2018, of which the Reporting Person's spouse is trustee. Read SEC document |
| December 28, 2018 Filed Feb 14, 2022 17:19 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GiftCommon Stock | 57,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,795 Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 17:40 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 18,584 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001567619-18-007640 · doc1.xml · derivative · entry 8 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,950 Underlying: Common Stock · 18,584 shares Expires 2028-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 17:40 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 3,306 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001567619-18-007640 · doc1.xml · derivative · entry 7 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,985 Underlying: Common Stock · 3,306 shares Expires 2026-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 17:40 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001567619-18-007640 · doc1.xml · derivative · entry 6 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2027-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 100% of the shares subject to the option on July 18, 2018, subject to the continuing service of the Reporting Person on the vesting date. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 17:40 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 18,584 | $6.31 | $117,265.04 |
DisclosureSEC source: 0001567619-18-007640 · doc1.xml · nonDerivative · entry 5 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 17:40 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 3,306 | $5.46 | $18,050.76 |
DisclosureSEC source: 0001567619-18-007640 · doc1.xml · nonDerivative · entry 4 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 17:40 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 150,000 | $4.11 | $616,500.00 |
DisclosureSEC source: 0001567619-18-007640 · doc1.xml · nonDerivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2018 Filed Dec 10, 2018 17:40 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 994 | $9.13 | $9,075.22 |
DisclosureSEC source: 0001567619-18-007640 · doc1.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,787 F1 · shares: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 17:26 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $9.36 | $0.00 |
DisclosureSEC source: 0001140361-18-033053 · doc1.xml · derivative · entry 4 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-07-17 F4 · derivative.exercise_date: The stock option vests and becomes exercisable contingent upon achievement of certain regulatory milestones. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 17:26 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $9.36 | $0.00 |
DisclosureSEC source: 0001140361-18-033053 · doc1.xml · derivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-07-17 F3 · derivative.exercise_date: The stock option vests and becomes exercisable contingent upon achievement of certain product development milestones. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 17:26 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $9.36 | $0.00 |
DisclosureSEC source: 0001140361-18-033053 · doc1.xml · derivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-07-17 F2 · derivative.exercise_date: The stock option vests and becomes exercisable contingent upon achievement of certain stock price milestones. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 17:26 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $9.36 | $0.00 |
DisclosureSEC source: 0001140361-18-033053 · doc1.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-07-17 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on August 18, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 09:04 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 14,866 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001140361-18-032462 · doc1.xml · derivative · entry 4 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,534 Underlying: Common Stock · 14,866 shares Expires 2028-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 09:04 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $7.04 | $0.00 |
DisclosureSEC source: 0001140361-18-032462 · doc1.xml · derivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2027-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 09:04 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 14,866 | $6.31 | $93,804.46 |
DisclosureSEC source: 0001140361-18-032462 · doc1.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 09:04 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 24,000 | $7.04 | $168,960.00 |
DisclosureSEC source: 0001140361-18-032462 · doc1.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 09:05 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 3,307 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001140361-18-032316 · doc1.xml · derivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,291 Underlying: Common Stock · 3,307 shares Expires 2026-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 09:05 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 3,307 | $5.46 | $18,056.22 |
DisclosureSEC source: 0001140361-18-032316 · doc1.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 18:23 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 178,400 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001140361-18-009665 · doc1.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,400 Underlying: Common Stock · 178,400 shares Expires 2028-02-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 16:36 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 15,211 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001140361-18-009074 · doc1.xml · derivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,598 Underlying: Common Stock · 15,211 shares Expires 2026-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 16:36 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 15,211 | $5.46 | $83,052.06 |
DisclosureSEC source: 0001140361-18-009074 · doc1.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2018 Filed Dec 10, 2018 17:40 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 2,000 | $6.02 | $12,040.00 |
DisclosureSEC source: 0001567619-18-007640 · doc1.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,793 F1 · shares: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 08, 2017 Filed Dec 8, 2017 19:06 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 600 | $5.07 | $3,039.00 |
DisclosureSEC source: 0001140361-17-045528 · doc1.xml · nonDerivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,409 F3 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $5.01 to $5.10 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 19:06 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 2,800 | $4.99 | $13,966.96 |
DisclosureSEC source: 0001140361-17-045528 · doc1.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,809 F2 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.88 to $5.10 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 19:06 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 4,888 | $4.92 | $24,072.42 |
DisclosureSEC source: 0001140361-17-045528 · doc1.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,009 F1 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.77 to $5.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| December 05, 2017 Filed Dec 5, 2017 21:04 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 5,065 | $4.93 | $24,975.52 |
DisclosureSEC source: 0001140361-17-045127 · doc1.xml · nonDerivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,121 F3 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.70 to $5.10 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 21:04 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 7,956 | $4.98 | $39,624.06 |
DisclosureSEC source: 0001140361-17-045127 · doc1.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,056 F2 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.85 to $5.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:04 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 4,100 | $4.53 | $18,577.92 |
DisclosureSEC source: 0001140361-17-045127 · doc1.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 F1 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.29 to $4.60 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 17:10 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001140361-17-034179 · doc1.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-08-30 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 100% of the shares subject to the option on July 18, 2018, subject to the continuing service of the Reporting Person on the vesting date. Read SEC document |
| April 21, 2017 Filed Apr 25, 2017 17:10 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $7.04 | $0.00 |
DisclosureSEC source: 0001140361-17-016748 · doc1.xml · derivative · entry 1 Quinn Anthony · CIK 0001532219 · Director · interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2027-04-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three equal monthly installments beginning on May 21, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.